

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
 File Information Unit
 Crystal Plaza Three, Room 1D01
 2021 South Clark Place
 Arlington, VA
 Telephone: (703) 308-2733

FEB 22 2005

In re Application of

Application Number

08/186,269

Filed

1-25-95

Paper No. 121

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 6840299 column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Wayne J. Poteau
 Signature
WAYNE J. POTEAU
 Typed or printed name

2-22-05

Date

FOR PTO USE ONLY

Approved by: WJ

(initials) FEB 22 2005

Unit: _____

Registration Number, if applicable

415-1077

Telephone Number

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.



US005840299A

United States Patent

[19]

Bendig et al.

[11] Patent Number: 5,840,299

[45] Date of Patent: Nov. 24, 1998

[54] **HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4**

[75] Inventors: **Mary M. Bendig**, London; **Olivier J. Léger**, Hertfordshire; **José Saldanha**, Enfield Middlesex; **S. Tarren Jones**, Radlett, all of United Kingdom; **Ted A. Yednock**, Fairfax, Calif.

[73] Assignee: **Athena Neurosciences, Inc.**, South San Francisco, Calif.

[21] Appl. No.: 561,521

[22] Filed: Nov. 21, 1995

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 186,269, which is a continuation-in-part of PCT/US95/01219 Jan. 25, 1995, abandoned.

[51] Int. Cl. ⁵ A61K 39/395; C07K 16/28; C12P 21/08; C12N 15/13

[52] U.S. Cl. 424/133.1; 424/130.1; 424/141.1; 424/143.1; 424/144.1; 424/153.1; 424/154.1; 424/173.1; 435/7.1; 435/7.2; 435/7.21; 435/7.24; 435/69.6; 435/172.3; 435/251.3; 435/320.1; 530/387.3; 530/388.73; 530/388.75; 530/388.22; 536/23.53

[58] Field of Search 424/150.1, 133.1, 424/141.1, 143.1, 144.1, 153.1, 154.1, 173.1; 435/69.6, 172.3, 252.3, 320.1, 7.1, 7.2, 7.21, 7.24; 536/23.4, 23.5, 23.53; 530/387.1, 387.3, 388.2, 388.22, 388.7, 388.73, 388.75

References Cited

U.S. PATENT DOCUMENTS

5,260,210 11/1993 Rubin et al. 435/240.23
5,530,101 6/1996 Queen et al. 530/387.3

FOREIGN PATENT DOCUMENTS

239400 9/1987 European Pat. Off. C12N 15/00
330506 8/1989 European Pat. Off. C07K 15/06
WO 90/07861 7/1990 WIPO C12P 21/00
WO 91/03252 3/1991 WIPO A61K 37/10
91/05038 4/1991 WIPO C12N 5/06
WO 93/15764 8/1993 WIPO A61K 39/395

OTHER PUBLICATIONS

Lisak et al. J. Neurol. Sciences 62: 281-293 (1983).
Teitelbaum et al. PNAS 89: 137-141 (1992).
Weiner et al. Science 259: 1321-1324 (1993).
Racke et al. J. Neuroimmunol. 46: 175-184 (1993).
Karussis et al PNAS 90: 6400-6404 (1993).

Cannella et al. Ann Neurol. 37: 424-435 (1995).
Washington et al. Ann Neurol 35: 89-97 (1994).
Dore-Dauly et al. in *Frontiers in Cerebral Vascular Biology: Transport and its Regulation* (eds) Dreues and Betz Plenum Press Ny 1993 pp. 243-248.

Monshizadegan et al., "VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes", 1993, *Agents Actions* 39, pp. C177-C179.
Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation", 1991, *Protein Engineering*, vol. 4, No. 7, pp. 773-783.

Yednock et al. "Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha 4\beta 1$ integrin", 1991, *Letters to Nature*, vol. 356, pp. 63-66.

W. J. Harris and S. Emery, "Therapeutic antibodies—the coming of age", 1993, *Tibtech*, vol. 11, pp. 42-45.

S. C. Emery and J. R. Adair, "Humanised monoclonal antibodies for therapeutic applications", 1994, *Exp. Opin. Invest. Drugs*, vol. 3, pp. 241-251.

S. M. Edgington, "How Sweet It Is: Selectin-Mediating Drugs", 1992, *BioTechnology*, vol. 10, pp. 383-389.

Ellices et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site", 1990, *Cell*, vol. 60, pp. 577-584.

Dijkstra et al., "Multiple sclerosis: some possible therapeutic opportunities", 1993, *Tips Reviews*, vol. 14, pp. 124-129.

A. Mountain and J.R. Adair, "Engineering Antibodies for Therapy", 1992, *Biotech Genetic Engineering Reviews*, vol. 10, pp. 10-13.

P.A. Ward and M.S. Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy", 1994, *Therapeutic Immunol*, vol. 10, pp. 165-171.

L. K. Jolliffe, "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering", 1993, *Intern Rev Immunol*, vol. 10, pp. 241-250.

Albelda Faseb J. 8: 504-512 (1994).

Kahan Curr Opin Immunology 4: 553-560 (1992).

Natanson et al. Ann Intern Med. 120: 771-783 (1994).

Dalakas Ann. Neurol. 37(51): 52-513 (1995).

Paul (ed) *Fundamental Immunology* Raven Press NY 1993 p. 242 only.

Primary Examiner—Lila Feisee

Assistant Examiner—Phillip Gabel

Attorney, Agent, or Firm—Townsend & Townsend & Crew LLP

[57] ABSTRACT

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.